GT Biopharma, Inc. (filing identifies issuer as OXIS International, Inc.) — 2014 Form 10-K
Filing identity and period: The supplied filing is OXIS International, Inc.’s annual report for the fiscal year ended December 31, 2014, not a filing under the company name in the request. Financial comparisons below are fiscal 2014 versus fiscal 2013; the filing does not provide standalone fourth-quarter results.
Business context
OXIS reported a shift toward biotechnology drug development through its subsidiary Oxis Biotech, after limited nutraceutical operations. Its preclinical candidates target triple-negative breast cancer (OXS-2175) and multiple myeloma and associated bone lesions (OXS-4235). The company relied on outside consultants and third-party manufacturers and reported just two employees at year-end.
Financial performance and position
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $61,000 | $368,000 |
| Gross profit | $4,000 | $142,000 |
| Operating expenses, primarily SG&A | $2.400 million | $935,000 |
| Operating loss | $2.396 million | $793,000 |
| Net loss | $23.489 million | $501,000 |
| Net loss per share, basic and diluted | $0.04 | $0.01 |
| Net cash used in operating activities | $1.749 million | $442,000 |
- Revenue fell about 83%; product revenue was $28,000, with an additional $33,000 of license revenue in 2014. Gross margin was about 7%, versus about 39% in 2013.
- The net loss included a $15.963 million expense from remeasurement of warrant and derivative liabilities and $5.146 million of interest expense. The filing attributes the higher interest expense to additional notes payable; much of the derivative and interest-related expense was noncash.
- Year-end cash was $855,000, up from $43,000. Current assets were $882,000, current liabilities $29.828 million, and working capital deficit $28.946 million. Total liabilities were $30.462 million against total assets of $888,000.
- Current liabilities included a $21.581 million warrant liability, $1.207 million of current convertible debentures, $252,000 of demand notes, and $691,000 settlement note payable. The filing reports no off-balance-sheet arrangements.
- Shares outstanding increased from 573.1 million to 591.7 million during 2014; 599.9 million were outstanding as of March 27, 2015. The filing also reports hundreds of millions of outstanding warrants, creating substantial potential dilution.
Material changes, outlook, and risks
- SG&A rose by $1.465 million, primarily due to stock-based compensation and consulting tied to biotech development. The company did not actively market products in 2014.
- Management said year-end cash could fund administrative expenses for 12 months, but also expected annualized administrative expenses to approach $5 million and said additional capital would be needed. A $2.05 million convertible-debenture placement was completed in March 2015; further fundraising was planned. These statements do not remove the going-concern risk.
- The auditor and management both cited substantial doubt about the company’s ability to continue as a going concern, given recurring losses, limited cash, and dependence on financing and future operations. The financial statements contain no adjustments for a possible failure to continue operations.
- After year-end, OXIS reported an exclusive worldwide ID4 license, with royalties of 3% of net sales and 25% of sublicensing revenue, plus up to $700,000 in specified development and approval milestones. It also licensed three ADC candidates from MCIT: a $500,000 fee, reimbursement of up to $1.125 million in development costs, and potential further payments of $22.75 million plus royalties if specified conditions are met.
- Management reported ineffective disclosure controls and internal control over financial reporting, including material weaknesses associated with inadequate segregation of duties and risk of executive override. A new full-time CFO was hired in November 2014.
- Other notable items include a $33,000 inventory write-off, settlement of litigation over a sun-care and skin-care product license in exchange for cash and a perpetual royalty, and significant debt and warrant terms that include conversion or exercise features and potential dilution.
Most important facts for investors to verify
- Confirm the issuer: the provided document is an OXIS International, Inc. 10-K, despite the request naming GT Biopharma, Inc.
- Review the complete audited statements and debt disclosures, including the composition and valuation of the $21.581 million warrant liability and the terms, defaults, and maturities of convertible and other debt.
- Assess cash runway against expected spending, the status and terms of post-year-end financing, and the company’s ability to raise further capital.
- Quantify potential dilution from outstanding warrants, options, convertible securities, and later financing; verify authorized-share capacity and conversion provisions.
- Track remediation of the disclosed control weaknesses and the status, costs, and development progress of the licensed drug and ADC programs.
- Check filing text inconsistencies: it refers to OXS-4235 as a lead candidate but also mentions OXS-4135 in the ID4 license discussion; the precise licensed compound and program terms should be confirmed.